Other B cell and antibody-modulating agents, including intravenous immunoglobulin (IvIg), transmembrane activator and calcium modulator and cyclophilin ligand (TACI) fusion proteins, and antibodies or small-molecule inhibitors to CD19, CD22, CD79a and b, B lymphocyte stimulator (BLyS), spleen tyrosine kinase (Syk) and a proliferation-inducing ligand (APRIL), are all suggested for new possible uses in the management of T2DM (11). This evidence concerns the gene CD79A and type 2 diabetes mellitus.